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H EMaL YTIC uremic syndrome (HUS) is a disorder 
characterized by hemolysis, thrombocytopenia, and 
renal failure. This syndrome may be epidemic, primary, 
familial, associated with autoimmune illness such as SLE, 
or due to cyclosporine (CyA) therapy. We have previously 
reported the first patient successfully treated with FK 506 
to control Cy A-induced HUS. I Although FK 506 was used 
only as substitution therapy, this patient's response has 
raised the hope that FK 506 might reduce the recurrence 
rate in renal transplant patients who have previously 
developed renal failure due to HUS. We will update our 
experience with renal transplant patients who have previ-
ously developed renal failure due to HUS and are subse-
quently treated with FK 506. In addition, we discuss one 
complicated patient who developed a syndrome very sim-
ilar to HUS for the first time while receiving FK 506. 
PATIENTS AND METHODS 
All patients receiving renal transplants under FK 506 with the 
diagnosis of HUS as the cause of renal failure in their native 
kidneys or in transplanted renal grafts are included in this series. 
Four patients with primary HUS and one patient with familial 
HUS were included. In addition, there were two patients with loss 
of renal function due to CyA-induced HUS. An additional patient 
with SLE, previous splenectomy for thrombocytopenia, and 
subsequent development of thrombocytopenia and thrombosis in 
a renal graft will be discussed. 
The immunosuppression protocol has been described previous-
ly.2.3 General goals of management include rapid tapering of 
prednisone and discontinuance if possible. and progressive rapid 
reductions in FK 506 dosage until the minimum quantity is 
attained. All patients receive Bactrim and acyclovir prophylactic 
therapy for pneumocystis and CMV. 
RESULTS 
Primary and Familial HUS 
From September 1989 to December 1990 five patients with 
histories of renal failure due to HUS in the native kidneys 
received cadaveric renal transplants at the University of 
Pittsburgh under FK 506 (Table l). One patient (5) devel-
oped HUS (diarrhea, microangiopathic hemolytic anemia, 
thrombocytopenia and renal failure) at age 3 months. 
Although renal function and the hematologic abnormalities 
improved, the patient experienced three relapses of HUS 
in 1 month and developed irreversible renal failure. A 
maternal aunt died of HUS at 1 year of age. The first 
cadaveric renal transplant was performed at age 11 
months. He was treated with corticosteroids, Cy A, aspi-
rin, and heparin. Five days posttransplant he developed 
gross hematuria, thrombocytopenia, hemolytic anemia, 
Table1. Patients With History of HUS Transplant Under FK 506' 
Patient Age 
1 32 
2 10 
3 3 
4 8 
5 11 mas 
'20% recurrence rate. 
tFamllial HUS. 
Graft No. Months Outcome 
5 13 Functioning 
20 Functioning 
8 Functioning 
7 Functioning 
2 0.5 tRecurred 
and worsening graft function. Despite a reduction in Cy;' 
dosage, addition of azathioprine and hemodialysis, a,. 
allograft nephrectomy was performed 10 weeks after trans-
plantation, which resulted in improvement of the hemato-
logic abnormalities. 
At 4 years of age a second cadaveric renal transplant 
was performed under FK 506. Postoperative treatment 
included heparin and corticosteroids. The allograft func-
tioned well until 5 days after surgery when gross hema-
turia, hemolytic anemia, and oliguria developed. He was 
initially treated with Persantine and plasmapheresis with-
out effect. On the seventh postoperative day defibrotide 
and human gamma globulin were substituted for these 
agents but the HUS persisted. On the fifteenth postopera-
tive day an allograft nephrectomy was performed with 
complete resolution of hematologic abnormalities. 
The remaining four patients with primary HUS have 
excellent function and have no evidence of recurrent 
HUS. Patient I had lost four previous grafts under CyA, 
but we could not document recurrence of HUS as the 
cause in any graft. 
eyA-lnduced HUS 
Two patients with Cy A-induced HUS resulting in loss of 
renal function have been transplanted under FK 506. The 
first pati~nt was a 33-year-old man who developed HUS 
after an orthotopic liver transplant. This patient was the 
first patient treated with FK 506 for HUS and has been 
previously reported. I He had chronic renal failure due to 
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Fig 1. Clinical course of a patient with CyA-induced HUS during 
tapering of FK 506 dosage. 
Cy A at the time HUS developed. After a rapid recovery 
from HUS upon initiation of FK 506. the patient's hema-
tologic picture worsened with rapid reduction in FK 506 
dosage (Fig O. When the FK 506 dosage was restored to 
an intermediate level, the platelet count also rose to an 
intermediate but adequate level. The patient's renal func-
tion, however, worsened and dialysis was required. A 
renal transplant was performed approximately 1 year later. 
After 18 months the patient has no evidence for recur-
rence. A slow and deliberate decrease in FK 506 dosage 
has been conducted since the kidney transplantation. 
The second patient lost a cadaveric renal allograft due to 
CyA-induced HUS. The cause of renal failure in his native 
kidneys was focal sclerosing glomerulonephritis (FSGS). 
A second transplant was performed on January 14, 1991. 
Mter 7 months his hematologic picture is normal and graft 
function is excellent. There has been no evidence for 
recurrent HUS or FSGS. 
THROMBOCYTOPENIA IN A RENAL TRANSPLANT 
PATIENT UNDER FK 506 
A 36-year-old woman with renal failure due to SLE re-
ceived a cadaveric renal transplant on May 4, 1990. 
Thrombocytopenia (50,000 cells) was present at the time 
SLE was first discovered in 1978. Persistent thrombocy-
topenia (minimum 20,000 cells) prompted a splenectomy in 
1982. After splenectomy, the platelet count was approxi-
mately 200,000 except during flares when platelet counts 
fell to approximately 500-900. 
Following transplantation, prednisone was rapidly ta-
pered and discontinued within 1 month. Two months 
posttransplant creatinine was 1.2 mg/dL and platelet count 
664,000, and the patient complained of pain in knees and 
generalized aches. Changes in FK 506 dosage and platelet 
count are illustrated in Fig 1. The hematologic picture was 
normal until the FK 506 dose was transiently decreased 
from 8 mg twice per day to 6 mg twice daily. Platelet count 
briefly fell from 672,000 to 588,000 and recovered after FK 
506 was again increased to 8 mg twice daily. Seven months. 
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posttransplant the patient developed dyspnea and a dry 
cough. Severe dyspnea prompted an admission in which 
bronchiolitis obliterans was diagnosed on lung biopsy. 
Despite FK 506 levels of 1.0 ng/mL (therapeutic) the 
dosage was reduce to 6 mg twice daily and 60 mg of 
prednisone was added. Eight days later she was admitted 
with a platelet count of 30,000 and creatinine of 2.7 mg/dL. 
FK 506 was discontinued and azathioprine was substi-
tuted. 
A renal biopsy performed on January 17, 1991 revealed 
widespread glomerular capillary thrombosis. Daily plas-
mapheresis, vincristine, and platelet transfusions were 
given until February 27, 1991 when renal function and 
platelet count improved. During this admission. however, 
total bilirubin never rose greater than 0.5 mg/dL although 
LDH reached 743 lUlL. This admission was also compli-
cated by CMV esophagitis and later CMV pneumonitis. 
Leukopenia. thought to be related to CMV and gancyclo-
vir, also developed. Hematology consultation during that 
admission questioned whether high-dose Bactrim therapy 
for possible pneumocystis. CMV infection. or heparin 
infusions contributed to the thrombocytopenia. At latest 
follow-up creatinine is 1.0 mg/dL on azathioprine and 
prednisone. 
DISCUSSION 
Recurrence of hemolytic uremic syndrome after renal 
transplantation occurs frequently. The pathogenesis of 
HUS remains essentially unknown and may not be identi-
cal for all forms. 
Our recent preliminary experience suggests that FK 506 
may be an effective substitute therapy in CyA-induced 
HUS. Both patients with CyA-induced HUS in this series 
have not developed recurrence and both currently have 
excellent graft function. In our first patient, the platelet 
count fell when FK 506 was rapidly tapered but later 
remained stable when a much slower dose reduction was 
performed. This may suggest that the HUS was only under 
control in the early treatment period and potentially active. 
Great care should be exercised in reducing the dosage of 
FK 506 in these patients. 
FK 506 may also allow patients with primary HUS to 
obtain renal allografts without a high risk of recurrence. 
None of the patients with primary HUS, and without the 
familial form. developed a recurrence after transplanta-
tion. However. patients with familial or rapidly recurrent 
HUS under CyA seem to be at great risk of recurrence 
under FK 506 therapy. Although we have treated only one 
such patient, it is clear that FK 506 may not prevent 
recurrence of all types of HUS. The patients who are most 
likely to benefit from FK 506 therapy and the poor prog-
nostic indicators will be determined by treatment of larger 
number of these patients. 
The patient with a HUS-like syndrome is very compli-
cated but may suggest that de novo HUS is possible with 
FK 506 therapy. Problematic issues include a previous 
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history of persistent thrombocytopenia resulting in sple-
nectomy, SLE (which is associated with TIP and HUS), 
the absence of hyperbilirubinemia (suggesting minimal 
hemolysis), and the development of other factors that 
could cause thrombocytopenia (CMV infection, ganciclo-
vic therapy, high-dose Bactrim therapy). Despite these 
confounding problems, ouc limited experience certainly 
does not rule out the possibility that FK 506 may cause 
HUS. Interestingly, the changes in platelet count and the 
onset of the HUS-like syndrome was associated with a 
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reduction in FK 506 dosage. This parallels the experience 
of our patient with CyA-induced HUS. It is possible that 
FK 506 was actually controlling an autoimmune process 
leading to thrombocytopenia in this lupus patient. 
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